Roxadustat in CKD and transplant patients: A new era in anemia management
The aim of this study was to evaluate the efficacy and safety of Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the management of anemia in patients with chronic kidney disease (CKD), including hemodialysis-dependent (HDD), non-dialysis-dependent (NDD), and renal...
Saved in:
| Main Authors: | Muhammad Tassaduq Khan, Sidrah Rashid, Syed Hasan farooq, Sabahat Sarfaraz, Rashid bin Hamid, Naranjan Lal |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Liaquat University of Medical and Health Sciences
2025-03-01
|
| Series: | Liaquat Medical Research Journal |
| Subjects: | |
| Online Access: | http://121.52.154.206/index.php/LMRJ/article/view/1284 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Issues on clinical application of hypoxia-inducible factor prolyl hydroxylase inhibitor Roxadustat
by: TU Yan, et al.
Published: (2020-01-01) -
A Case Report of Hypothyrotropin Hypothyroidism Caused by Roxadustat
by: YAN Xuelian, et al.
Published: (2025-03-01) -
Roxadustat has risks of reversible central hypothyroidism in patients undergoing hemodialysis: a single-center retrospective cohort study
by: Emiko Otsuka, et al.
Published: (2024-12-01) -
Low cholesterol levels are good markers for central hypothyroidism in case with dialysis using roxadustat
by: Serina Kita, et al.
Published: (2024-09-01) -
Randomized Trial of Lower-Dose Roxadustat Efficacy and Safety in Non–Dialysis-Dependent CKD-Associated Anemia
by: Ping Li, et al.
Published: (2025-04-01)